MedTrace Logo

DNA Diagnostics for Minimizing Metabolic Side-Effects of Antipsychotics

NCT00752960 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2008-09-16

No results posted yet for this study

Summary

The purpose of this study is to assess patients treated with the antipsychotics aripiprazole (Abilify®), olanzapine (Zyprexa®), quetiapine (Seroquel®), risperidone (Risperdal®), or ziprasidone (Geodon®) and to identify genetic variations more commonly found in individuals who develop diabetic metabolic signs and symptoms, which include changes in blood lipids, blood glucose, blood pressure, and body weight.

Conditions

  • Psychoses

Sponsors & Collaborators

  • Hartford Hospital

    collaborator OTHER

  • University of Kentucky

    collaborator OTHER

  • Genomas, Inc

    lead INDUSTRY

Principal Investigators

  • Gualberto Ruano, MD, PhD · Genomas, Inc

Eligibility

Min Age
18 Years
Max Age
59 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2009-12-31
Completion
2009-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00752960 on ClinicalTrials.gov